Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Figs Inc (FIGS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Figs Inc vs Neurocrine Biosciences Inc — how do they compare? Figs Inc trades at $14.26 (market cap $2.39B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 7× Figs Inc's market cap, and Figs Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.

FIGSNBIX
Market Cap
$2.39B$16.76B
Sector
Consumer CyclicalHealth
52-Week High
$17.12$185.50
52-Week Low
$6.57$123.10
Enterprise Value
$2.15B$16.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Figs Inc

FIGS stock surged 26.87% to $14.26, supported by strong Q2 2026 earnings that beat estimates with $0.11 EPS and 29% revenue growth. The technical outlook is bullish with moving averages aligned positively, while fundamentals show improving profitability with a net income margin of 8.72% and robust gross margins near 69%. Recent news highlights institutional buying and raised full-year guidance, reflecting strong operational momentum.

The outlook remains positive given consistent earnings beats and upward revenue revisions, though the stock's high P/E of 43.21 suggests premium valuation risks. Key investor risks include cost pressures from tariffs and freight, alongside competitive threats in the healthcare apparel space. Analyst consensus is bullish with a $19.50 price target, indicating potential upside from current levels.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Figs Inc

FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.

Read more on FIGS

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX